Critical Healthcare Market to 2017 - Shift of Focus towards PCC, Factor Concentrates and Antithrombins due to Better Safety and Efficacy Profiles


#3309

86pages

GBI Research

$ 3500

In Stock


GBI Research, the leading business intelligence provider, has released its latest research, Critical Healthcare Market to 2017 - Shift of Focus towards PCC, Factor Concentrates and Antithrombins due to Better Safety and Efficacy Profiles. The report provides in-depth analysis of drivers and barriers that impact the global critical health market. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Researchs team of industry experts. The report analyzes the markets for factor XIII concentrates, fibrinogen concentrates, albumins, antithrombins and prothrombin complex concentrates in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain), and Japan. 

This includes treatment usage patterns, average annual cost of therapy and market size forecast until 2017 for the key geographies as well as the leading therapeutic segments. The report also provides information on the R&D product pipeline and explores the competitive landscape, including major players in the critical healthcare market. Finally, the report includes analysis on mergers and acquisitions (M&As) in the critical healthcare market.

GBI Research indicates that the global critical healthcare market is still an untapped market, with small numbers of players contributing to a major proportion of the overall critical health market. The market grew at very sluggish growth rate in the historic period, possible due to the unavailability of many of the products in certain markets, especially in the US. GBI Research estimates that the overall critical healthcare market in 2010 was worth $1,130.7m, representing a Compound Annual Growth Rate (CAGR) of 5% between 2002 and 2010. The global critical healthcare market is expected to grow at a moderate rate of 2.8% between 2010 and 2017, and is expected to reach $1,372.4m in 2017. 

The increased availability and usage of PCC, albumin products and factor concentrates for the management of various bleeding complications, and high risk surgical settings such as trauma, PPH, cardiac surgery and liver diseases, will drive the market in future. Approvals and launches of new products such as Riastap, Corifact and Atryn, and the anticipated launch of recombinant products, will boost growth of the critical healthcare market in the forecast period.

Scope

The report covers - 

  • Data and analysis on the critical healthcare market in the leading geographies of the world the US, the UK, Germany, France, Italy, Spain, and Japan.
  • Annualized market data for the critical healthcare market that includes markets for factor XIII concentrate, fibrinogen concentrate, antithrombin, prothrombin complex concentrate and albumin from 2002 to 2010, with forecasts to 2017.
  • Market data on the geographical landscape and therapeutic landscape, including market size, market share, cost of therapy, sales volume and treatment usage patterns such as disease population, diagnosis population and prescription population.
  • Key drivers and restraints that have had a significant impact on the market.
  • The competitive landscape of the global critical healthcare market, including top companies benchmarking. The key companies studied in this report are CSL, Octapharma, Baxter, Grifols and LFB.
  • Key M&A activities that took place in 2010 and 2011 in the critical healthcare market.

Reasons to buy

The report will assist business development and marketing executives to strategize their product launches, by allowing them to -
  
  • Align your product portfolio to the markets with high growth potential.
  • Build effective strategies to launch their pipeline products by identifying potential geographies.
  • Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
  • Develop key strategic initiatives by studying the key strategies of top competitors.
  • Devise a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.
  • Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.
Table of Contents

1 Table of Contents

1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 8

2 Critical Healthcare Market to 2017 Introduction 9
2.1 GBI Research Report Guidance 9

3 Critical Healthcare Market to 2017 Global Overview 10

4 Critical Healthcare Market to 2017 Geographical Landscape 12
4.1 Introduction 12
4.2 The US 13
4.2.1 Revenue 13
4.3 Top Five Countries of Europe 14
4.3.1 Revenue 14
4.4 Japan 16
4.4.1 Revenue 16

5 Critical Healthcare Market to 2017 Therapeutic Landscape 17
5.1 Factor XIII Concentrate 17
5.1.1 Introduction 17
5.1.2 Revenue 18
5.1.3 Geographical Segmentation 21
5.1.4 Cost of Treatment 22
5.1.5 Treatment Usage Pattern 24
5.2 Drivers and Restraints 25
5.2.1 Drivers 26
5.2.2 Restraint 26
5.3 Marketed Products 27
5.3.1 Fibrogammin P / Corifact 27
5.4 Antithrombin (AT) Market 27
5.4.1 Introduction 27
5.4.2 Revenue 29
5.4.3 Geographical Segmentation 31
5.4.4 Cost of Treatment 32
5.4.5 Treatment Usage Pattern 33
5.5 Drivers and Restraints 35
5.5.1 Drivers 36
5.5.2 Restraints 36
5.6 Marketed Products 37
5.6.1 Thrombate III (Antithrombin III human) 37
5.6.2 Anbinex (Grifols SA) 37
5.6.3 Kybernin (CSL Behring GmbH) 38
5.6.4 Aclotine (Laboratory of French Split and Biotechnology) 38
5.6.5 ANTITHROMBIN III (Baxter) 38
5.6.6 Neuart (Mitsubishi Tanabe Pharma Corporation) 39
5.6.7 Atryn 39
5.7 Fibrinogen Concentrate Market 40
5.7.1 Introduction 40
5.7.2 Revenue 41
5.7.3 Geographical Segmentation 42
5.7.4 Cost of Treatment 45
5.7.5 Treatment Usage Pattern 46
5.8 Drivers and Restraints 47
5.8.1 Drivers 48
5.8.2 Barriers 48
5.9 Marketed Products 48
5.9.1 Haemocomplettan/Riastap 48
5.10 Albumin 49
5.10.1 Introduction 49
5.10.2 Revenue 50
5.10.3 Geographical Segmentation 52
5.10.4 Cost of Treatment 53
5.10.5 Treatment Usage Pattern 55
5.11 Drivers and Restraints 56
5.11.1 Drivers 56
5.11.2 Restraints 56
5.12 Marketed Products 57
5.12.1 Albuminar (CSL Behring) 57
5.12.2 Human Albumin Biotest, solution for infusion (Biotest) 57
5.12.3 Buminate 25% (Baxter) 58
5.12.4 Human Albumin Grifols 25% (Grifols SA) 58
5.13 Prothrombin Complex Concentrate Market (PCC) 58
5.13.1 Introduction 58
5.13.2 Revenue 60
5.13.3 Revenue Breakup 62
5.13.4 Geographical Segmentation 63
5.13.5 Cost of Treatment 64
5.13.6 Treatment Usage Pattern 65
5.14 Drivers and Restraints 66
5.14.1 Drivers 66
5.14.2 Barriers 67
5.15 Marketed Products 67
5.15.1 Beriplex P/N 67
5.15.2 Feiba 68

6 Critical Healthcare Market to 2017 - Product Pipeline 69
6.1 Introduction 69
6.1.1 rFXIII (Novo Nordisk A/S) 71

7 Critical Healthcare Market to 2017 Competitive Landscape 72
7.1 CSL Limited 72
7.1.1 Company Overview 72
7.1.2 SWOT Analysis 73
7.2 Octapharma AG 73
7.2.1 Company Overview 73
7.2.2 SWOT Analysis 74
7.3 Baxter International Inc. 75
7.3.1 SWOT Analysis 75
7.4 Grifols SA (Grifols) 76
7.4.1 Company Overview 76
7.4.2 SWOT Analysis 77
7.5 LFB S.A. (LFB) 78
7.5.1 Company Overview 78
7.5.2 SWOT Analysis 78

8 Critical Healthcare Market to 2017 Mergers & Acquisitions Landscape 79
8.1 LFB Biotechnologies Completes Acquisition of GTC Biotherapeutics 79
8.2 Grifols Completes Acquisition of Talecris Biotherapeutics 79

9 Critical Healthcare Market to 2017 Appendix 80
9.1 Market Definitions 80
9.2 Abbreviations 80
9.3 Research Methodology 81
9.3.1 Coverage 81
9.3.2 Secondary Research 81
9.3.3 Primary Research 82
9.4 Therapeutic Landscape 82
9.4.1 Epidemiology-based Forecasting 83
9.5 Geographical Landscape 85
9.6 Pipeline Analysis 85
9.7 Competitive Landscape 85
9.7.1 Expert Panel Validation 85
9.8 Contact Us 85
9.9 Disclaimer 85
9.10 Sources 86
Table 1: Critical Healthcare Market, Global Revenue ($m), 2002-2010 11
Table 2: Critical Healthcare Market, Global Revenue ($m), 2010-2017 11
Table 3: Critical Healthcare Market, The US, Revenue ($m), 2002-2010 14
Table 4: Critical Healthcare Market, The US, Revenue, ($m), 2010-2017 14
Table 5: Critical Healthcare Market, Top Five Countries of Europe, Revenue ($m), 2002-2010 15
Table 6: Critical Healthcare Market, Top Five Countries of Europe, Revenue ($m), 2010-2017 15
Table 7: Critical Healthcare Market, Japan, Revenue ($m), 2002-2010 16
Table 8: Critical Healthcare Market, Japan, Revenue ($m), 2010-2017 16
Table 9: Critical Healthcare Market, Global, Factor XIII Concentrate, Revenue ($000), 2002-2010 18
Table 10: Critical Healthcare Market, Global, Factor XIII Concentrate, Revenue ($000), 2010-2017 18
Table 11: Critical Healthcare Market, Global, Factor XIII Concentrate, Revenue Segmentation ($000), 2002-2010 21
Table 12: Critical Healthcare Market, Global, Factor XIII Concentrate, Revenue Segmentation ($000), 2010-2017 22
Table 13: Critical Healthcare Market, Global, Factor XIII Concentrate, Cost of Therapy ($), 2002-2010 23
Table 14: Critical Healthcare Market, Global, Factor XIII Concentrate, Cost of Therapy ($), 2010-2017 23
Table 15: Critical Healthcare Market, Global, Factor XIII Concentrate, Treatment Usage Pattern, 2002-2010 24
Table 16: Critical Healthcare Market, Global, Factor XIII Concentrate, Treatment Usage Pattern, 2010-2017 24
Table 17: Critical Healthcare Market, Global, Antithrombin, Revenue ($000), 2002-2010 29
Table 18: Critical Healthcare Market, Global, Antithrombin, Revenue ($000), 2010-2017 30
Table 19: Critical Healthcare Market, Global, Antithrombin Revenue Segmentation ($000), 2002-2010 31
Table 20: Critical Healthcare Market, Global, Antithrombin Revenue Segmentation ($000), 2010-2017 32
Table 21: Critical Healthcare Market, Global, Antithrombin Cost of Therapy ($), 2002-2010 33
Table 22: Critical Healthcare Market, Global, Antithrombin Cost of Therapy ($), 2010-2017 33
Table 23: Critical Healthcare Market, Global, Antithrombin, Treatment Usage Pattern (000), 2002-2010 34
Table 24: Critical Healthcare Market, Global, Antithrombin, Treatment Usage Pattern (000), 2010-2017 34
Table 25: Critical Healthcare Market, Global, Fibrinogen Concentrate, Revenue ($m), 2002-2010 41
Table 26: Critical Healthcare Market, Global, Fibrinogen Concentrate, Revenue ($m), 2010-2017 41
Table 27: Critical Healthcare Market, Global, Fibrinogen Concentrate, Revenue Segmentation ($000), 2002-2010 43
Table 28: Critical Healthcare Market, Global, Fibrinogen Concentrate, Revenue Segmentation ($000), 2010-2017 43
Table 29: Critical Healthcare Market, Global, Fibrinogen Concentrate, Cost of Therapy ($), 2002-2010 45
Table 30: Critical Healthcare Market, Global, Fibrinogen Concentrate, Cost of Therapy ($), 2010-2017 45
Table 31: Critical Healthcare Market, Global, Fibrinogen Concentrate, Treatment Usage Pattern, 2002-2010 47
Table 32: Critical Healthcare Market, Global, Fibrinogen Concentrate, Treatment Usage Pattern, 2010-2017 47
Table 33: Critical Healthcare Market, Global, Albumin Revenue ($m), 2002-2010 51
Table 34: Critical Healthcare Market, Global, Albumin Revenue ($m), 2010-2017 51
Table 35: Critical Healthcare Market, Global, Albumin Revenue Segmentation ($m), 2002-2010 52
Table 36: Critical Healthcare Market, Global, Albumin Revenue Segmentation ($m), 2010-2017 53
Table 37: Critical Healthcare Market, Global, Albumin Cost of Therapy ($), 2002-2010 54
Table 38: Critical Healthcare Market, Global, Albumin Cost of Therapy ($), 2010-2017 54
Table 39: Critical Healthcare Market, Global, Albumin, Number of Patients on Albumin Therapy (000), 2002-2010 55
Table 40: Critical Healthcare Market, Global, Albumin, Number of Patients on Albumin Therapy (\'000), 2010-2017 55
Table 41: Critical Healthcare Market, Global, PCC, Revenue ($m), 2002-2010 61
Table 42: Critical Healthcare Market, Global, PCC, Revenue ($m), 2010-2017 61
Table 43: Critical Healthcare Market, Global, PCC, Revenue Segmentation ($m), 2002-2010 63
Table 44: Critical Healthcare Market, Global, PCC, Revenue Segmentation ($m), 2010-2017 64
Table 45: Critical Healthcare Market, Global, PCC, Cost of Therapy ($), 2002-2010 65
Table 46: Critical Healthcare Market, Global, PCC, Cost of Therapy ($), 2010-2017 65
Table 47: Critical Healthcare Market, Global, PCC, Number of Patients on PCC, 2002-2010 65
Table 48: Critical Healthcare Market, Global, PCC, Number of Patients on PCC, 2010-2017 66
Table 49: Critical Healthcare Market, Product Pipeline by Indication, 2011 70
Figure 1: Critical Healthcare Market, Global Revenue ($m), 2002-2017 11
Figure 2: Critical Healthcare Market, Global Revenue Share (%), 2010 12
Figure 3: Critical Healthcare Market, The US, Revenue ($m), 2002-2017 13
Figure 4: Critical Healthcare Market, Global, Revenue ($m), 2002-2017 14
Figure 5: Critical Healthcare Market, Top Five Countries of Europe, Revenue ($m), 2002-2017 15
Figure 6: Critical Healthcare Market, Japan, Revenue ($m), 2002-2017 16
Figure 7: Critical Healthcare Market, Global, Factor XIII Concentrate, Revenue ($\'000), 2002-2017 18
Figure 8: Critical Healthcare Market, Global, Factor XIII Concentrate Market Breakup (%), 2010 19
Figure 9: Critical Healthcare Market, Global, Factor XIII Concentrate, Revenue Segmentation ($\'000), 2002-2017 21
Figure 10: Critical Healthcare Market, Global, Factor XIII Concentrate, Cost of Therapy ($), 2002-2017 22
Figure 11: Critical Healthcare Market, Global, Factor XIII Concentrate, Treatment Usage Pattern, 2002-2017 24
Figure 12: Critical Healthcare Market, Global, Factor XIII Concentrate Market, Drivers and Restraints, 2010 25
Figure 13: Critical Healthcare Market, Global, Antithrombin, Revenue ($\'000), 2002-2017 29
Figure 14: Critical Healthcare Market, Global Antithrombin Market Breakup (%), 2010 30
Figure 15: Critical Healthcare Market, Global, Antithrombin, Revenue Segmentation ($m), 2002-2017 31
Figure 16: Critical Healthcare Market, Global, Antithrombin Cost of Therapy ($), 2002-2017 32
Figure 17: Critical Healthcare Market, Global, Antithrombin, Treatment Usage Pattern (\'000), 2002-2017 33
Figure 18: Critical Healthcare Market, Global Antithrombin Market, Drivers and Restraints, 2010 35
Figure 19: Critical Healthcare Market, Global, Fibrinogen Concentrate, Revenue ($m), 2002-2017 41
Figure 20: Critical Healthcare Market, Global, Fibrinogen Concentrate, Revenue Segmentation ($m), 2002-2017 42
Figure 21: Critical Healthcare Market, Global Fibrinogen Concentrate Market Breakup (%), 2010 43
Figure 22: Critical Healthcare Market, Global, Fibrinogen Concentrate, Cost of Therapy ($), 2002-2017 45
Figure 23: Critical Healthcare Market, Global, Fibrinogen Concentrate, Treatment Usage Pattern, 2002-2017 46
Figure 24: Critical Healthcare Market, Global Fibrinogen Concentrate Market, Drivers and Restraints, 2010 47
Figure 25: Critical Healthcare Market, Global, Albumin Revenue ($m), 2002-2017 51
Figure 26: Critical Healthcare Market, Global, Albumin Revenue Segmentation ($m), 2002-2017 52
Figure 27: Critical Healthcare Market, Global, Albumin Cost of Therapy ($), 2002-2017 54
Figure 28: Critical Healthcare Market, Global, Albumin, Number of Patients on Albumin Therapy, 2002-2017 55
Figure 29: Critical Healthcare Market, Global Albumin Market, Drivers and Restraints, 2010 56
Figure 30: Critical Healthcare Market, Global, PCC, Revenue ($m), 2002-2017 61
Figure 31: Critical Healthcare Market, Global, PCC Market Breakup (%), 2010 62
Figure 32: Critical Healthcare Market, Global, PCC, Revenue Segmentation ($m), 2002-2017 63
Figure 33: Critical Healthcare Market, Global, PCC, Cost of Therapy ($), 2002-2017 64
Figure 34: Critical Healthcare Market, Global, PCC, Number of Patients on PCC, 2002-2017 65
Figure 35: Critical Healthcare Market, Global PCC Market, Drivers and Restraints, 2010 66
Figure 36: Critical Healthcare Market, SWOT Analysis of CSL Behring, 2010 73
Figure 37: Critical Healthcare Market, SWOT Analysis of Octapharma, 2010 74
Figure 38: Critical Healthcare Market, SWOT Analysis of Baxter, 2010 75
Figure 39: Critical Healthcare Market, SWOT Analysis of Grifols, 2010 77
Figure 40: Critical Healthcare Market, SWOT Analysis of LFB, 2010 78
Figure 41: GBI Research Market Forecasting Model 84